New Intellectual Property to Support Minimally Invasive
Transplantation of Trails of Neural Stem Cells
- Executed
Agreements with University of California, San Diego and Dr. James Guest -
-
InVivo Provisional Patent Application Filed -
InVivo Therapeutics Holdings Corp. (NVIV) today announced an
innovative strategy for the treatment of chronic spinal cord injury
(SCI). The company will focus its research efforts for chronic SCI on
Bioengineered Neural Trails™. Bioengineered Neural Trails are injectable
combinations of biomaterials and neural stem cells (NSCs) delivered
using minimally-invasive surgical instrumentation and techniques to
create trails across the chronic injury site. To support this strategy,
InVivo has entered into agreements with the University of California,
San Diego (UC San Diego) and James Guest, M.D., Ph.D., to expand the
company’s intellectual property portfolio. InVivo entered into an
exclusive license agreement with UC San Diego for issued patent US
9,011,410 titled “Spinal Multisegmental Cell and Drug Delivery System,”
and into an assignment agreement with Dr. Guest for issued patent US
7,666,177 titled “Method and System for Cellular Transplantation in the
Spinal Cord.” InVivo also has filed a provisional application in support
of the Bioengineered Neural Trails program titled “Methods and Systems
for Delivery of a Trail of a Therapeutic Substance.”
“Our goal is to restore neuronal connectivity and thereby promote
neurological recovery in people with chronic SCI,” said Tom Ulich, M.D.,
Chief Scientific Officer of InVivo. “Our minimally-invasive therapeutic
approach is to bridge the spinal cord lesion at the time of implantation
with a trail of NSCs delivered in an injectable and biodegradable soft,
gel-like scaffold. We look forward to presenting our preclinical results
in the spinal cords of small and large animals during the Key Opinion
Leader Event and Company Update on Thursday. ”
Mark Perrin, Chief Executive Officer and Chairman of InVivo, said, “We
are excited about our novel Bioengineered Neural Trails program for the
treatment of chronic spinal cord injury. The newly secured patents along
with our provisional patent application provide the intellectual
property foundation for our Bioengineered Neural Trails program.”
The company will discuss its innovative strategy for the treatment of
chronic SCI during the KOL Event and Company Update webcast at 5:15PM ET
on Thursday. The webcast will be broadly accessible through http://lifesci.rampard.com/20151203.
To learn more about our approach to chronic spinal cord injury, visit
the InVivo Therapeutics website:
http://www.invivotherapeutics.com/research-clinical-development/pipeline/bioengineered-neural-trails/.
About Bioengineered Neural Trails™
Bioengineered Neural Trails are injectable combinations of biomaterials
and neural stem cells (NSCs) delivered using minimally invasive surgical
instrumentation and techniques to create trails across the chronic
spinal cord injury site. InVivo’s Bioengineered Neural Trails program is
currently being advanced preclinically by the Research and Development
team at InVivo for the treatment of chronic spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold™ received the
2015 Becker’s Healthcare Spine Device Award. The publicly-traded company
is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be
identified by words such as "believe," "anticipate," "intend,"
"estimate," "will," "may," "should," "expect,"
“designed to,” “potentially,” and similar expressions, and include
statements regarding the expected impact of the company’s Bioengineered
Neural Trails program for the treatment of chronic SCI. Any
forward-looking statements contained herein are based on current
expectations, and are subject to a number of risks and uncertainties.
Factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the company’s ability to execute on its
development strategy and to obtain FDA approval for future clinical
studies; the expected benefits and efficacy of the company’s products
and technology in connection with the treatment of spinal cord injuries;
the availability of substantial additional funding for the company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and other risks
associated with the company’s business, research, product development,
regulatory approval, marketing and distribution plans and strategies
identified and described in more detail in the company’s Annual Report
on Form 10-K for the year ended December 31, 2014, and its other filings
with the SEC, including the company’s Form 10-Qs and current reports on
Form 8-K. The company does not undertake to update these forward-looking
statements.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20151202005376r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20151202005376/en/
Copyright Business Wire 2015